Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components
- 1 December 2005
- Vol. 23 (48-49) , 5688-5697
- https://doi.org/10.1016/j.vaccine.2004.11.077
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Cell Surface Tumor Endothelium Marker 8 Cytoplasmic Tail-independent Anthrax Toxin Binding, Proteolytic Processing, Oligomer Formation, and InternalizationJournal of Biological Chemistry, 2003
- Use of a Promoter Trap System in Bacillus anthracis and Bacillus subtilis for the Development of Recombinant Protective Antigen-Based VaccinesInfection and Immunity, 2003
- AnthraxAnnual Review of Microbiology, 2001
- Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of AnthraxScience, 2001
- Involvement of Domain 3 in Oligomerization by the Protective Antigen Moiety of Anthrax ToxinJournal of Bacteriology, 2001
- The expression of the protective antigen of Bacillusanthracis in Bacillus subtilisJournal of Applied Microbiology, 1998
- Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracisLetters in Applied Microbiology, 1998
- Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigsVaccine, 1995
- Construction of Bacillus anthracis mutant strains producing a single toxin componentJournal of General Microbiology, 1993
- Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracisGene, 1989